No increased cardiovascular risk detected for new diabetes medication

An international, multidisciplinary team has found that lixisenatide, a member of a class of glucose-lowering drugs frequently prescribed in Europe to patients with diabetes, did not increase risk of cardiovascular events including heart failure. These results are the first to be reported on the cardiovascular safety of a glucagon-like peptide 1 receptor agonist.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1F8eoqP